Synlogic (LTS:0A8U) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0A8U Synlogic Inc LTS:0A8U
30 GF Score
Price $1.17
GF Value $0.03
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Synlogic Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Synlogic's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $0.00 Mil. Synlogic's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $0.00 Mil. Synlogic's annualized EBITDA for the quarter that ended in Jun. 2026 was $-2.17 Mil. Synlogic's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Synlogic's Debt-to-EBITDA or its related term are showing as below:

LTS:0A8U's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.215
* Ranked among companies with meaningful Debt-to-EBITDA only.

Synlogic  (LTS:0A8U) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Synlogic Debt-to-EBITDA Related Terms

Synlogic Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Synlogic's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Synlogic Debt-to-EBITDA Chart

Synlogic Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Synlogic Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

LTS:0A8U vs LSTA, PASG, HIND: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, Synlogic's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Synlogic Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Synlogic's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Synlogic's Debt-to-EBITDA falls into.


LTS:0A8U
30GF Score
Synlogic Inc LTS:0A8U
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Synlogic Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Synlogic's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -1.005
=0.00

Synlogic's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -2.172
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Is Synlogic (LTS:0A8U) Overvalued in 2026?

Based on GuruFocus' analysis, Synlogic stock appears to be overvalued. The current stock price of $1.17 is trading 3800% above its estimated GF Value™ of $0.03. GuruFocus considers Synlogic to be Significantly Overvalued.

Key valuation signals for LTS:0A8U:

  • Debt-to-EBITDA:
  • GF Value™: $0.03 vs. price of $1.17 (3800% above fair value)
  • GF Score™: 30/100 with 1 warning sign

No single metric tells the full story. See the LTS:0A8U stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Synlogic Business Description

Other Exchanges SYBX:USA
Address PO Box 30, Winchester, MA, USA, 01890
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. The pipeline drug candidates includes: labafenogene marselecobac (SYNB1934); SYNB1353 Classical Homocystinuria (HCU); SYNB8802 Enteric Hyperoxaluria; and SYNB2081 Gout. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one operating segment: Discovery and development of Synthetic Biotics.
30GF Score

Get the complete analysis for LTS:0A8U

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.17
Price
$0.03
GF Value